Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

• Publication date

  2016-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1272/jnms.83.81PMID 27180793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

  2014cited by this paper
• Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

  2014cited by this paper
• Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

  2013cited by this paper
• Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

  2012cited by this paper
• Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

  2011cited by this paper
• Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.

  2011cited by this paper
• Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5‐fluorouracil) has a synergistic effect in estrogen receptor‐positive breast cancer

  2011cited by this paper
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

  2010cited by this paper
• Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer

  2010cited by this paper
• The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

  2010cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• Combining endocrine agents with chemotherapy: Which patients and what sequence?

  2008cited by this paper
• Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.

  2005cited by this paper
• Fulvestrant: pharmacokinetics and pharmacology

  2004cited by this paper
• ICI 182,780 (Faslodex™)

  2000cited by this paper

• Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer.

  2016cites this paper